Cormorant Global Healthcare Master Fund, LP
CIK 1618442 · last filed 2025-08-01
Cormorant Global Healthcare Master Fund, LP is a corporate insider who has filed 14 SEC Form 4 insider transactions across 10 companies since 2016. The most recent filing, for BMEA, was dated Aug 1, 2025. Across all open-market trades the lifetime net is +$440.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $184.8M across reported positions. The firm reports its address in Boston, MA. 108 SEC filings were submitted jointly with Bihua Chen.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$184.75M
10
14
$440.85M
Filer Profile
52ND FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMEA | 10%+ Owner | 3,570,872 | $1.74 | $6.21M | $48.00M | 3 | 2025-08-01 |
| CRBP | 10%+ Owner | 2,349,231 | $8.12 | $19.08M | $21.01M | 1 | 2024-09-24 |
| EYPT | 10%+ Owner | 7,288,479 | $4.23 | $30.83M | $31.47M | 1 | 2024-04-22 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | 10%+ Owner | 11,231,000 | $28.00 | $314.47M | $137.84M | 2 | 2023-10-25 |
| MLTX | 10%+ Owner | 8,367,498 | $12.51 | $104.68M | $100.80M | 1 | 2023-10-04 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | 616,786 | $8.05 | $4.97M | $0 | 1 | 2022-01-13 | |
| TYRA | 757,432 | $22.03 | $16.69M | $20.00M | 1 | 2021-09-21 | |
| IMRX | 10%+ Owner | 1,702,628 | $4.27 | $7.27M | $33.00M | 1 | 2021-08-05 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | 2,223,022 | $199.92 | $444.43M | $28.50M | 1 | 2021-03-18 | |
| KINETA, INC./DE (PTI) Delisted | 10%+ Owner | 180,017 | — | — | $20.24M | 2 | 2016-12-06 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-01 | BMEA | — | — | $0 | EDGAR |
| 2024-09-24 | CRBP | Buy (P) | +1,050,000 | $21.01M | EDGAR |
| 2024-06-13 | BMEA | Grant (A) | — | $0 | EDGAR |
| 2024-04-22 | EYPT | Buy (P) | +1,745,295 | $31.47M | EDGAR |
| 2023-10-25 | Ambrx Biopharma, Inc. (AMAM) Delisted | Buy (P) | +5,229,244 | $36.56M | EDGAR |
| 2023-10-04 | MLTX | Buy (P) | +1,759,272 | $100.80M | EDGAR |
| 2023-04-17 | Ambrx Biopharma, Inc. (AMAM) Delisted | Buy (P) | +10,391,584 | $101.28M | EDGAR |
| 2023-04-03 | BMEA | Buy (P) | +1,600,000 | $48.00M | EDGAR |
| 2022-01-13 | Vigil Neuroscience, Inc. (VIGL) Delisted | Conv (C) | +2,467,144 | $0 | EDGAR |
| 2021-09-21 | TYRA | Mixed | +4,279,728 | $20.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.